Alector (NASDAQ:ALEC) Insider Grace Wong-Sarad Sells 4,079 Shares

Alector, Inc. (NASDAQ:ALEC) insider Grace Wong-Sarad sold 4,079 shares of the company’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $2.50, for a total value of $10,197.50. Following the transaction, the insider directly owned 118,903 shares of the company’s stock, valued at approximately $297,257.50. This represents a 3.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Grace Wong-Sarad also recently made the following trade(s):

• On Friday, December 5th, Grace Wong-Sarad sold 4,753 shares of Alector stock. The stock was sold at an average price of $1.21, for a total transaction of $5,751.13.
• On Wednesday, December 3rd, Grace Wong-Sarad sold 8,056 shares of Alector stock. The shares were sold at an average price of $1.12, for a total transaction of $9,022.72.

Alector Stock Up 7.1%

NASDAQ:ALEC traded up $0.17 during midday trading on Thursday, hitting $2.56. 1,310,675 shares of the company were exchanged, compared to its average volume of 940,846. Alector, Inc. has a fifty-two week low of $0.87 and a fifty-two week high of $3.40. The company has a market capitalization of $279.42 million, a PE ratio of -2.39 and a beta of 0.64. The company has a current ratio of 3.76, a quick ratio of 3.76 and a debt-to-equity ratio of 0.17. The company has a fifty day simple moving average of $1.83 and a 200 day simple moving average of $2.03.

Alector (NASDAQ:ALEC) last posted its earnings results on Wednesday, February 25th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.05. The business had revenue of $6.24 million for the quarter, compared to analysts’ expectations of $1.78 million. Alector had a negative return on equity of 123.02% and a negative net margin of 156.03%. As a group, equities analysts anticipate that Alector, Inc. will post -1.88 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ALEC shares. Weiss Ratings restated a “sell (d-)” rating on shares of Alector in a research report on Wednesday, January 21st. BTIG Research upgraded shares of Alector from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. Wall Street Zen raised shares of Alector from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Morgan Stanley reissued an “underweight” rating on shares of Alector in a report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $3.25.

Alector News Summary

Here are the key news stories impacting Alector this week:

• Positive Sentiment: Q4 results beat expectations — Alector reported GAAP EPS of ($0.34) vs. the consensus of ($0.39) and revenue of $6.24M vs. $1.78M expected; the revenue outperformance is the primary catalyst for the move higher. Company Press Release
• Positive Sentiment: Unusually large call buying — Traders bought ~3,578 call options (about +790% vs. typical daily volume), signaling short-term bullish positioning by options market participants. (Market options activity reported 2/25/26)
• Neutral Sentiment: Coverage & earnings write-ups — Multiple outlets posted earnings snapshots and the company business update summarizing the quarter; these provide context but largely reiterate the beats above. Business Insider: Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update SFGate: Alector Q4 Earnings Snapshot
• Neutral Sentiment: Short-interest data appears inconsistent — Reports show “0 shares” and NaN changes for February, implying a likely data/reporting issue rather than a meaningful shift in short positioning; treat this as noisy/unreliable information for now.
• Negative Sentiment: Insider sale — Director Grace Wong‑Sarad sold 4,079 shares at an average $2.50 (SEC filing disclosed). While the sale is relatively small versus total float and insiders still hold stock, investors sometimes view insider selling as a cautionary signal. SEC Filing: Insider Sale

Institutional Investors Weigh In On Alector

Institutional investors have recently modified their holdings of the company. Virtu Financial LLC purchased a new stake in shares of Alector during the fourth quarter worth about $34,000. Invesco Ltd. grew its stake in Alector by 45.3% in the 4th quarter. Invesco Ltd. now owns 279,468 shares of the company’s stock worth $436,000 after acquiring an additional 87,157 shares during the period. Mackenzie Financial Corp raised its holdings in Alector by 132.7% in the 4th quarter. Mackenzie Financial Corp now owns 660,168 shares of the company’s stock valued at $1,001,000 after acquiring an additional 376,456 shares during the last quarter. XTX Topco Ltd lifted its stake in shares of Alector by 501.8% during the 4th quarter. XTX Topco Ltd now owns 592,839 shares of the company’s stock worth $925,000 after purchasing an additional 494,326 shares during the period. Finally, Ikarian Capital LLC boosted its holdings in shares of Alector by 174.0% during the fourth quarter. Ikarian Capital LLC now owns 2,082,606 shares of the company’s stock worth $3,249,000 after purchasing an additional 1,322,606 shares during the last quarter. Hedge funds and other institutional investors own 85.83% of the company’s stock.

Alector Company Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.